Estimates Revisions Acurx Pharmaceuticals, Inc.
Stocks
ACXP
US00510M2035
Biotechnology & Medical Research
|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.580 USD | -1.25% |
|
-10.73% | -36.55% |
| 05-20 | Acurx Pharmaceuticals Highlights FDA's Guidance That Could Accelerate Approval Path for Ibezapolstat | CI |
| 05-12 | Acurx Pharmaceuticals, Inc., Q1 2026 Earnings Call, May 12, 2026 |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
EBIT - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | - | |||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| - | |||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
Turnover
Earnings Per Share (EPS)
EBIT
- Stock Market
- Stocks
- ACXP Stock
- Consensus Acurx Pharmaceuticals, Inc.
- Estimates Revisions
Select your edition
All financial news and data tailored to specific country editions
